Marc Schmalzing
Overview
Explore the profile of Marc Schmalzing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagler L, Schmalzing M, Isberner N, Schoen C, Gernert M
Clin Rheumatol
. 2025 Mar;
PMID: 40088401
No abstract available.
2.
Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, et al.
RMD Open
. 2025 Mar;
11(1).
PMID: 40037922
Objectives: Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major...
3.
Goller S, Dege T, Schmalzing M, Schmieder A
Eur J Dermatol
. 2025 Feb;
34(6):685-686.
PMID: 39912483
No abstract available.
4.
Gernert M, Schwaneck E, Schmalzing M
Z Rheumatol
. 2025 Jan;
84(1):48-56.
PMID: 39853385
Neutropenia in rheumatoid arthritis (RA) is a problem that often needs to be addressed. Side effects of basic antirheumatic treatment, infections or substrate deficiencies are common causes; however, T‑cell large...
5.
Guggenberger K, Riedling L, Kern D, Werner R, Vogt M, Frohlich M, et al.
Rheumatol Int
. 2025 Jan;
45(1):27.
PMID: 39804420
Background: Diagnosis of Giant Cell Arteritis (GCA) and Polymyalgia rheumatica (PMR) may be challenging as many patients present with non-specific symptoms. Superficial cranial arteries are predilection sites of inflammatory affection....
6.
Gernert M, Muller T, Schweiker L, Schmalzing M, Frohlich M, Nagler L, et al.
Arthritis Res Ther
. 2024 Dec;
26(1):210.
PMID: 39663523
Background: Clonal T cell populations are frequently detected in patients with rheumatic diseases. The relevance of this finding is often uncertain, as the clinical spectrum can range from being asymptomatic...
7.
Schmalzing M, Gernert M, Frohlich M, Henes J, Schwindl N, Zerhusen L, et al.
Front Immunol
. 2024 Nov;
15:1436639.
PMID: 39512343
Objective: In severe cases of systemic sclerosis (SSc), autologous hematopoietic stem cell transplantation (aHSCT) is superior compared to cyclophosphamide. But treatment related morbidity and mortality have to be considered. To...
8.
Winter C, Theuersbacher J, Guggenberger K, Frohlich M, Schmalzing M, Bley T, et al.
Klin Monbl Augenheilkd
. 2024 Oct;
PMID: 39389553
Background: Giant-cell arteritis (GCA) requires immediate diagnosis and therapy. The University Hospital of Würzburg established the Centre for Giant-cell Arteritis (ZeRi) to improve interdisciplinary collaboration. Aim Of The Study: Retrospective...
9.
Strunz P, Risser L, Englbrecht M, Witte T, Froehlich M, Schmalzing M, et al.
Front Immunol
. 2024 Sep;
15:1445680.
PMID: 39238648
Background: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is...
10.
Labinsky H, Nagler L, Krusche M, Griewing S, Aries P, Kroiss A, et al.
Rheumatol Int
. 2024 Aug;
44(10):2055.
PMID: 39180534
No abstract available.